Guard Therapeutics International AB (SE:GUARD)
:GUARD
GUARD Stock Chart & Stats
kr1.38
-kr0.80(-4.00%)
At close: 4:00 PM EST
kr1.38
-kr0.80(-4.00%)
Day’s Range― - ―
52-Week Rangekr1.10 - kr27.00
Previous CloseN/A
Volume1.94K
Average Volume (3M)44.15K
Market Cap
kr26.30M
Enterprise Value-kr23.53M
Total Cash (Recent Filing)kr100.48M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta0.63
Next Earnings
May 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.81
Shares Outstanding20,167,631
10 Day Avg. Volume59,609
30 Day Avg. Volume44,153
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.65
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.04
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
No Debt On Balance SheetA debt-free balance sheet materially lowers refinancing and interest burdens, giving management flexibility to prioritize R&D and strategic partnerships. Over 2–6 months this reduces solvency risk and avoids near-term covenant or rollover pressures that can distract clinical programs.
Platform-focused A1M Drug DevelopmentA platform centered on A1M creates structural optionality: validated biology can be extended to multiple kidney indications and enable licensing or partnership opportunities. This durable business model can amplify R&D investment value if clinical proof points emerge.
Lean Organizational StructureA very small headcount reduces fixed overhead and can stretch available capital for core development activities. For a pre-revenue biotech, a lean structure supports outsourcable development and can preserve runway length absent immediate revenue.
Bears Say
No Revenue Across 2020–2025Sustained absence of revenue means the company remains entirely dependent on external financing or partnerships to fund operations. Over the medium term this increases dilution and strategic risk, and it signals lack of commercial validation that limits self-sustaining growth prospects.
Sustained Heavy Operating Cash BurnLarge, persistent negative operating cash flow rapidly depletes assets and forces recurring capital raises or partnerships. This materially raises funding risk and the likelihood of dilutive financing or program delays, constraining ability to complete clinical milestones without external support.
Sharply Weakened Balance Sheet And Falling Equity/assetsRapid erosion of equity and assets diminishes the company's financial buffer to absorb further losses and reduces negotiating power with partners and investors. Over months this worsens funding runway and elevates execution risk for ongoing development programs.
GUARD FAQ
What was Guard Therapeutics International AB’s price range in the past 12 months?
Guard Therapeutics International AB lowest stock price was kr1.10 and its highest was kr27.00 in the past 12 months.
What is Guard Therapeutics International AB’s market cap?
Guard Therapeutics International AB’s market cap is kr26.30M.
When is Guard Therapeutics International AB’s upcoming earnings report date?
Guard Therapeutics International AB’s upcoming earnings report date is May 13, 2026 which is in 33 days.
How were Guard Therapeutics International AB’s earnings last quarter?
Guard Therapeutics International AB released its earnings results on Feb 20, 2026. The company reported -kr0.81 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.81.
Is Guard Therapeutics International AB overvalued?
According to Wall Street analysts Guard Therapeutics International AB’s price is currently Overvalued.
Does Guard Therapeutics International AB pay dividends?
Guard Therapeutics International AB does not currently pay dividends.
What is Guard Therapeutics International AB’s EPS estimate?
Guard Therapeutics International AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Guard Therapeutics International AB have?
Guard Therapeutics International AB has 20,167,631 shares outstanding.
What happened to Guard Therapeutics International AB’s price movement after its last earnings report?
Guard Therapeutics International AB reported an EPS of -kr0.81 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 6.25%.
Which hedge fund is a major shareholder of Guard Therapeutics International AB?
Currently, no hedge funds are holding shares in SE:GUARD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Guard Therapeutics International AB
Guard Therapeutics International AB (publ), a pharmaceutical company, identifies, develops, and commercializes therapies for the diagnosis and treatment of acute kidney injuries in Sweden. It offers ROSGard, a biological drug candidate that prevents kidney damage by protecting, cleaning, and repairing the exposed cells and tissues. The company was formerly known as A1M Pharma AB (publ) and changed its name to Guard Therapeutics International AB (publ) in October 2019. Guard Therapeutics International AB (publ) was incorporated in 2008 and is based in Stockholm, Sweden.
Technical Analysis
Xbrane Biopharma AB
―
Ascelia Pharma AB
―
Intervacc AB
―
Immunicum AB
―
Corline Biomedical AB
―